---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-005399"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:32:40.888384+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sagimet reports positive Phase 2b NASH trial: denifanstat meets primary endpoints with statistical significance

## Summary
- NASH resolution without worsening fibrosis (≥2-point NAS reduction): 36% denifanstat vs 13% placebo (p=0.0022).
- Fibrosis improvement ≥1 stage without NASH worsening: 41% denifanstat vs 18% placebo (p=0.0051).
- MRI-PDFF ≥30% reduction: 65% denifanstat vs 21% placebo (p<0.0001).
- No treatment-related SAEs; discontinuation rate 19.6% denifanstat vs 5.4% placebo.

## SEC filing metadata
- accession: 0001104659-24-005399
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465924005399/0001104659-24-005399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465924005399/tm2333216d8_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-005399
- JSON: https://secwatch.observer/filing/0001104659-24-005399.json
- Plain text: https://secwatch.observer/filing/0001104659-24-005399.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.